Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Apr 02, 2026
- Pharmaceuticals
- R&D
Lilly’s Announcement Regarding Oral GLP-1 Foundayo™ (Orforglipron)
TOKYO, April 2, 2026 -- Chugai Pharmaceutical Co., Ltd. (hereafter “Chugai”, TOKYO: 4519) announced that Eli Lilly and Company (hereafter “Lilly”, NYSE: LLY) issued a news release on April 1, 2026 (local time) stating that the U.S. Food and Drug Administration (FDA) has approved FoundayoTM (orforglipron) for adults with obesity or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo can help individuals lose excess body weight and keep the weight off.
Discovered by Chugai, Foundayo is exclusively licensed to Lilly for global development and commercialization.
For the full text of Lilly's news release, please refer to the Latest News via the following link:
FDA approves Lilly’s FoundayoTM (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
https://investor.lilly.com/